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Abstract 
Background: Transmission‑blocking vaccines (TBVs) have become a focus of strategies to control and eventually 
eliminate malaria as they target the entry of sexual stage into the Anopheles stephensi mosquito thereby preventing 
transmission, an essential component of the parasite life cycle. Such vaccines are envisioned as complements to vac‑
cines that target human infection, such as RTS,S as well as drug treatment, and vector control strategies. A number of 
conserved proteins, including Pfs25, have been identified as promising TBV targets in research or early stage devel‑
opment. Pfs25 is a 25 kDa protein of Plasmodium falciparum expressed on the surface of zygotes and ookinetes. Its 
complex tertiary structure, including numerous cysteines, has led to difficulties in the expression of a recombinant 
protein that is homogeneous, with proper conformation, and free of glycosylation, a phenomenon not found in 
native parasite machinery.
Methods: While the expression and purification of Pfs25 in various systems, has been previously independently 
reported, here a parallel analysis of Pfs25 is presented to inform on the biochemical features of Pfs25 and their impact 
on functionality. Three scalable expression systems were used to express, purify, and evaluate Pfs25 both in vitro and 
in vivo, including the ability of each protein to produce functional antibodies through the standard membrane feed‑
ing assay.
Results: Through numerous attempts, soluble, monomeric Pfs25 derived from Escherichia coli was not achieved, 
while Pichia pastoris presented Pfs25 as an inhomogeneous product with glycosylation. In comparison, baculovi‑
rus produced a pure, monomeric protein free of glycosylation. The glycosylation present for Pichia produced Pfs25, 
showed no notable decrease in the ability to elicit transmission reducing antibodies in functional evaluation, while 
a reduced and alkylated Pfs25 (derived from plant and used as a control) was found to have significantly decreased 
transmission reducing activity, emphasizing the importance of ensuring correct disulfide stabilized conformation dur‑
ing vaccine design and production.
Conclusions: In this study, the biochemical features of Pfs25, produced from different expression systems, are 
described along with their impact on the ability of the protein to elicit functional antibodies. Pfs25 expressed using 
baculovirus and Pichia showed promise as candidates for vaccine development.
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Background
Malaria caused by Plasmodium falciparum is respon-
sible for nearly a half million deaths annually, based on 
the estimates from the WHO [1]. The emergence of drug-
resistant malaria strains over the last four decades has 
emphasized the desirability of the development of a safe 
and effective malaria vaccine. Vaccines play an impor-
tant role in strategies for eliminating and eradicating 
malaria [2]. Particularly valuable would be a vaccine that 
blocks parasite function at multiple stages of the life cycle 
including transmission from humans to mosquitoes [3]. 
Such transmission-blocking vaccines (TBVs) would not 
block disease in the vaccine recipients directly but rather 
would reduce the prevalence of malaria in a population 
thereby complementing current vector control strategies 
and increasing the efficacy of the RTS,S vaccine which 
blocks infection from mosquito to human [4]. To advance 
such TBVs, the identification of appropriate target anti-
gens, their expression, characterization, and preparation 
for experimental clinical testing is underway.
Malaria transmission requires transport of the Plas-
modium parasite to the gut of the female Anopheles ste-
phensi mosquito after feeding on an infected human. In 
the mosquito gut, the Plasmodium parasite undergoes 
sexual-stage development, replication, and invasion of the 
mosquito salivary glands leading to infectious sporozoites 
capable of infecting humans during the mosquito’s next 
blood meal [5]. As there are relatively few cells constitut-
ing the sexual stage in the mosquito, it has been proposed 
that vaccine induced neutralizing antibodies carried into 
the mosquito, as part of the blood meal, might be highly 
effective at halting the lifecycle of the Plasmodium para-
site [5]. Several conserved proteins, specifically those 
involved in sexual-stage parasite development, have 
been identified as potential targets. Antibodies raised to 
these targets, have shown activity to inhibit laboratory-
based assays of sexual stage parasite development thereby 
encouraging the advancement of candidate vaccines [6].
One of the primary targets for TBV development is the 
Pfs25 protein, an approximate 25  kDa sexual stage pro-
tein of P. falciparum, which is expressed on the surface 
of zygotes and ookinetes [6–8]. Pfs25 has a compact and 
unusual structure, which complicates its production and 
analysis [7, 9]. There are four-tandem epidermal growth 
factor (EGF)-like repeat motifs putatively anchored to the 
parasite surface by a glycosylphosphatidylinositol (GPI) 
moiety [10]. An additional complexity is added because 
Plasmodium parasites lack the N-linked glycosylation 
machinery, and Pfs25 contains multiple potential glyco-
sylation sites that could then be aberrantly glycosylated 
when expressed in recombinant eukaryotic systems [11]. 
Whether this non-native glycosylation might affect func-
tionality of Pfs25, especially as a TBV antigen, has not 
been comprehensively evaluated before in recombinant 
protein immunization. It seems likely that antibodies 
capable of interfering with Pfs25, will need to bind to the 
native configuration of the protein found on the parasite 
within the mosquito and that antibodies raised to a non-
native protein might not be very active.
Immunogenicity of Pfs25 has been reported in both 
animals and in human clinical trials [12, 13]. The expres-
sion and purification of recombinant Pfs25 for these 
studies has been reported using different systems includ-
ing yeast [11, 14–16], plant [17], Escherichia coli [18] 
and algae [19] along with delivery mechanisms for these 
reported proteins [20]. The objective was to compare 
these systems for the quality of Pfs25 obtained, includ-
ing whether proper folding of the recombinant proteins 
occurs, and the impact protein folding has on the elicita-
tion of functional antibodies. Three common expression 
systems (E. coli, Pichia pastoris, and baculovirus), which 
have been used for large-scale production of recombi-
nant proteins, were used. Further, the purified proteins 
were evaluated using in  vitro and in  vivo tests using a 
previously reported plant-expressed Pfs25 [17] as an 
additional control antigen. This information is intended 
as a starting point for the selection of preferred produc-
tion systems for vaccine generation and to inform the 




The Pfs25 sequence from 3D7 clone (ACCESSION 
P13829) Ala 22 to Thr 193, lacking the native signal 
sequence and GPI-anchor was used to produce recom-
binant Pfs25 in E. coli, Pichia, and baculovirus. The GPI 
anchor sequence functions poorly in heterologous eukar-
yotic system and was not included [21]. Codon optimi-
zation for each expression system was performed by 
DNA2.0 with a C-terminal hexa-histidine tag added to 
the coding region to facilitate affinity purification.
Escherichia coli
Pfs25 with and without additional N-terminal periplas-
mic signal sequence (encoding MKYLLPTAAAGLLL-
LAAQPAMA of Pectate Lyase B of Erwinia carotovora) 
and with 5′ NdeI and 3′ XhoI restriction sites was cloned 
into pET41a (Novagen) via standard cloning procedures. 
Resulting plasmids denoted as pET41a-peri-Pfs25 (with 
periplasmic signal peptide) and pET41a-Pfs25 (without 
signal peptide), were sequenced and verified.
Pichia
Briefly, two mutations were introduced (N112Q and 
N187Q) to avoid N-glycosylation [17]. The resulting 
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Pfs25 fragment with 5′ BamHI and 3′ EcoRI restric-
tion sites was cloned into pPIC9K (Thermo Fisher) in 
frame with alpha-factor secretion signal. The expression 
plasmid denoted pMBL003-Pfs25 was sequenced and 
verified. pMBL003-Pfs25 was transformed into Pichia 
pastoris BICC9682, and cells plated on YNBD(Yeast 
Nitrogen Base Dextrose) agar plates at 30  °C for 3 days. 
Approximately 100 clones were screened for the expres-
sion of Pfs25 and an additional 2000 clones on G418 
plates screened for multi-copy integrants.
Baculovirus
Synthetic pfs25 containing N112Q and N187Q muta-
tions as described in Pichia, with an additional N-termi-
nal secretion signal (MKFLVNVALVFMVVYISYIYAD 
from Honeybee Melittin) was cloned into pFastBac vec-
tor (Invitrogen) with BamHI (5′) and EcoRI (3′) sites 
and the resulting plasmid pFastBac-Pfs25 was sequence 
verified. The generation of recombinant virus followed 
Users’ Manual of Bac-to-Bac system (Invitrogen). Briefly, 
pFastBac-Pfs25 was transformed into E. coli DH10Bac 
to generate recombinant bacmid and colonies grown at 
37 °C for 48 h on LB agar plates containing Tetracycline 
(10  μg/ml), kanamycin (50  μg/ml), gentamycin (7  μg/
ml), IPTG (40  μg/ml) and X-Gal (5-bromo-4-chloro-3-
indolyl-β-d-galactopyranoside, 100  μg/ml), according to 
users’ manual. The bacmids from selected colonies were 
confirmed by PCR and sequencing, then used to trans-
fect Super Sf9 cells (Oxford Expression Technologies) for 
the generation of recombinant baculovirus stock (P1), 
using CellFECTIN II (Invitrogen) following Bac-to-Bac 
manual. P1 virus (approximately 14  ml) was harvested 
and stored at 4  °C protected from light. Two-milliliters 
of the P1 virus was used to amplify P2 baculovirus after 
infecting fresh super Sf9 cells at 27 °C for approximately 
90 h and similarly to produce high titer P3 virus; remain-
ing P1 baculovirus supernatant was stored at −80 °C. A 
P3 virus volume of 400 ml for further expression was har-
vested and titered using BacPAK titer kit (Clontech).
Escherichia coli protein expression
Several methods to express soluble Pfs25 in E. coli were 
used including cell lines BL21 (DE3) and BLR(DE3), co-
expression of protein disulfide bond isomerase (DsbC), 
expression in lower temperature (20 °C), and IPTG con-
centrations (1 and 0.25 mM). All of which did not yield 
sufficient quantity of soluble, monomeric Pfs25 for fur-
ther purification. Briefly, pET41a-Pfs25 (cytoplasmic) and 
pET41a-peri-Pfs25 (periplasmic) plasmids were trans-
formed in BL21 (DE3) and BLR (DE3), respectively, and 
clones were selected and verified. Expression induction at 
37 and 20 °C was carried out for 3 and 16 h, respectively 
at an optical density A600 of 0.8. Induced cultures were 
harvested by centrifugation for 10  min at 4  °C. The cell 
pellet was collected and lysed using BugBuster Protein 
Extraction Reagent (Novagen) per the manufacturer’s 
instructions. Soluble and insoluble fractions were sepa-
rated via centrifugation.
Pichia protein expression and purification
Approximately 100 clones of pMBL003-Pfs25 in Pichia 
pastoris were screened for protein expression in 2  ml 
deep well plates with 2 ml complex medium containing 
2 % dextrose for 2 days. Medium was then removed and 
replaced with 2 ml of complex medium with 1 % metha-
nol for 3 days, with 1 % methanol feed once a day. Sam-
ples were collected on the third day post induction. Three 
high-yield clones were identified by analyses with reduc-
ing SDS-PAGE (Pfs25 expression band at 20  kDa), and 
evaluated with anti-His (Qiagen) or anti-Pfs25 mAb 4B7 
[6, 22, 23] (BEI Resources) Western blots as described.
Pichia (G418 screening)
In parallel, clones were screened on YPD (Yeast pep-
tone dextrose) agar in the presence of G418 (0.5, 1 and 
2  mg/ml) in 96-well plates—corresponding to poten-
tial increased copies of gene of interest and hence, likely 
increased protein yield. G418 positive clones, including 
ten clones by 0.5  mg/ml G418, eight by 1  mg/ml G418, 
and two by 2 mg/ml G418 were subjected to small-scale 
expression as described earlier, which led to identifica-
tion of slightly better protein expressers. A selection of 
ten clones was then evaluated in 100 ml BMGY (Buffered 
Glycerol complex medium) and induced with BMMY 
(Buffered Methanol complex Medium) using 1 % metha-
nol feeding per day for 3 days followed by analysis (reduc-
ing SDS-PAGE). Two colonies, C6 and H4, produced 
similar yield and quality of Pfs25, and C6 was arbitrarily 
selected for 800 ml expression and further purification.
Purification
Supernatant from G418 (clone C6) was purified using 
Ni–NTA resin (Qiagen) using standard protocol. Briefly, 
200 ml supernatant was adjusted to 1000 ml with 50 mM 
Tris–HCl (pH 8.0), 150 mM NaCl, applied to column and 
washed (10 CV, column volume) with 5 mM Imidazole in 
50 mM Tris–HCl (pH 8.0), 150 mM NaCl. Proteins were 
eluted with 300 mM Imidazole in 50 mM Tris–HCl (pH 
8.0), 150 mM NaCl, analysed, pooled, and dialyzed into 
PBS buffer, pH 7.4. The pool was concentrated and fur-
ther purified by gel filtration (Superdex 75).
Baculovirus expression and purification
Using Super Sf9 cells, three different MOI’s (multiplic-
ity of infection, 1, 3, and 5) were screened at a 30  ml 
scale as well as uninfected cells (negative control). Post 
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infection (48 and 72 h), 1 ml of culture was collected and 
centrifuged for 5 min. The supernatant was analysed via 
reducing and non-reducing SDS-PAGE and Western 
blot. Based on analysis of Pfs25 post infection of 72 h, no 
significant difference between the three MOI’s tested was 
seen and further expression proceeded with MOI = 1 at 
100 ml and 72 h.
Purification
Supernatant was used for batch binding overnight with 
~2 ml of Ni–NTA resin (Qiagen, Cat No: 30410) at 4 °C 
on table top rocker platform. Two washing steps were 
used: Wash buffer (1): 1x PBS with 10  mM Imidazole, 
pH 7.2 (10 CV) and wash buffer (2): 1x PBS with 20 mM 
Imidazole, pH 7.2 (10 CV). Protein was eluted via a step 
gradient with elution buffers (1): 1x PBS with 50  mM 
Imidazole, pH 7.2 and Elution buffer and (2): 1x PBS with 
500  mM Imidazole, pH 7.2. Elution fractions were then 
analysed and those containing Pfs25 were pooled, con-
centrated, and further purified on Superdex 75 column.
Plant control protein
Pfs25 derived from Nicotiana benthamiana was provided 
by Fraunhofer CMB (Newark, DE) and utilized as a con-
trol antigen. The soluble protein, termed Pfs25MF1E, and 
encompassing amino acid 23–193 of the Pfs25 sequence, 
with a theoretical mass of 20,021 daltons is fully 
described in [17]. The protein was provided at 1.65 mg/
ml and in 20 mM Tris buffer containing 70 mM NaCl, pH 
8.0 as previously described [17].
SDS‑PAGE
The samples were used with either (1) 4X non-reducing 
NuPAGE LDS (Lithium dodecyl sulfate) sample buffer 
(non-reducing and non-boiled) or with reducing agent 
and heated to 95 °C for 5 min or (2) 4X SDS sample buffer 
and boiled for 10  min at 99  °C (reducing and boiled). 
SDS-PAGE gels (4–12 % NuPAGE Bis–Tris or 15 % Tris–
glycine) were loaded in a final volume of 20 μl/well and 
run at 150–200 V for 35–50 min in 1X MES or 1X SDS 
running buffer.
Western blotting
Following SDS-PAGE, proteins were transferred onto 
PVDF membrane and blocked in 5  % skim milk (1X 
Tris buffered saline, TBS) at room temperature for 1 h. 
Primary antibodies were prepared at 1:5000 dilutions 
of Penta His antibody (Qiagen Cat No:- 34460), 1:2000 
dilution of Anti-Pfs25 mAb 4B7 (BEI), or 1:1000 dilu-
tions of 1G2 (final 2 µg/ml) in 1 % skim milk in 1X TBS 
buffer containing 0.05 % Tween-20 (TBS-T). Blots were 
incubated in the primary antibody solution for 1  h at 
room temperature or overnight at 2–8  °C. Membranes 
were washed with 1X TBS-T buffer (3X for 10 min) and 
secondary antibody 1:1000 dilution of goat anti mouse 
IgG-HRP (Santa Cruz) or 1:4000 goat anti mouse IgG 
Alkaline Phosphatase (BioRad) in 1  % skim milk (1X 
TBS-T buffer) was added and incubated at room tem-
perature for 1  h. Membranes were then again washed 
with 1X TBS-T buffer (3X for 10 min). HRP labeled blots 
were developed with TMB (3,3,5,5′-Tetramethylbenzi-
dine) substrate. Alkaline Phosphatase labeled blots were 
developed using Bio-Rad Alkaline Phosphatase Conju-
gate Substrate Kit.
Kinetic endotoxin assay
Spectramax plus spectrophotometer (kinetic endotoxin 
assay) was used to quantify endotoxin content of purified 
Pfs25, with EndoSafe Endotoxin standard (Charles River), 
EndoSafe Lysate (Charles River), and EndoSafe LAL Rea-
gent Water (Charles River).
Parasite extract preparation
Mature gametocyte cultures were prepared as reported 
previously [24]. From the stage V gametocytes, zygote- 
and ookinete-stage parasites were induced in vitro using 
the method described by Ghosh et al. [25]. The parasite 
extract containing native Pfs25 was prepared by three 
times freeze-and-thaw of the P. falciparum NF54 game-
tocyte/zygote/ookinete parasites. The human serum and 
red blood cells used for the gametocyte cultures (extract 
preparation and SMFA) were purchased from Interstate 
Blood Bank (Memphis, TN).
Size exclusion HPLC (SE‑HPLC) analysis
SE-HPLC analysis for purified Pfs25 proteins from Pichia 
and baculovirus was performed on a BioAssist G3SWxl 
column (7.8  ×  300  mm, TOSOH Biosciences, King of 
Prussia, PA) with a Shimadzu Prominence UFLC HPLC 
system at a flow rate of 0.7 ml/min in 0.2 M sodium phos-
phate pH 6.8. A gel filtration standard (Bio-Rad, Hercu-
les, CA) was used in column calibration.
Reversed‑phase chromatography
Samples of Pfs25 were analysed using an Ultimate 3000 
UHPLC system (Thermo Scientific) with a 2.6  µm, 
2.1 × 150 mm C-18 column (Thermo Scientific) at a flow 
rate of 0.2 ml/min. C-18 column and auto-sampler tem-
peratures were set at 60 and 5  °C, respectively. The elu-
tion of Pfs25 was monitored using absorbance (214 nm). 
Mobile phase (A) consisted of water with 0.1  % trif-
luoroacetic acid (TFA) and mobile phase (B) consisted 
of acetonitrile with 0.1 % TFA with a gradient of: 1 % B 
(5 min), 1–20 % B (2 min), 20–50 % B (30 min), 50–99 % 
B (2 min), 99 % B (3 min), 99–1 % B (2 min), and 1 % B 
(5 min). The Pfs25 samples were also run without column 
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to determine sample recovery (82 ± 2 % for baculovirus 
protein and 70 ± 3 % recovery for Pichia protein).
Free thiol determination
Free thiol (number of free cysteine residues) in each 
protein sample was measured using Measure iT free 
thiol assay kit (Life Technologies, Carlsbad, CA) follow-
ing manufacturer’s instructions. Samples were diluted in 
either ultrapure water or 2 M guanidine-HCl and 50 μg 
of each Pfs25 sample was used for non-denaturing condi-
tions and 25 μg of each Pfs25 sample was used for dena-
turing conditions. A standard curve (R2  =  0.983) was 
constructed using known concentrations of reduced glu-
tathione. Fluorescence was measured using a SpectraMax 
M5 plate reader (Molecular Devices, Sunnyvale, CA).
Intact mass spectrometry
Intact masses of each sample (in duplicate) were meas-
ured using a SYNAPT G2 hybrid quadrupole/ion mobil-
ity/TOF mass spectrometer (Waters Corporation, 
Milford, MA) with the assistance of the Mass Spec-
trometry and Analytical Proteomics Laboratory at the 
University of Kansas. The instrument was operated 
in a sensitivity mode with all lenses optimized on the 
MH + ion from the control Leucine Enkephalin and sam-
ple cone voltage of 40 eV. Argon was admitted to the trap 
cell operated at 4  eV for maximum transmission. Spec-
tra were acquired at 9091 Hz pusher frequency covering 
the mass range from 100 to 3000 unified atomic mass 
unit and accumulating data for two seconds per cycle. 
Time to mass calibration was made with NaI cluster ions 
acquired under the same conditions. Mass spectra of 
[Glu1]-Fibrinopeptide B were acquired in parallel scans 
and doubly charged ions at m/z 785.8426 were used as a 
lock mass reference.
Samples were desalted via reversed phase PRP-1 col-
umn, 1 cm, 1 mm I.D. (Hamilton, 10 µm particles packed 
by hand) using a NanoAcquity chromatographic system 
(Waters Corporation) and solvents A (99.9 % H2O, 0.1 % 
formic acid) and B (99.9 % acetonitrile, 0.1 % formic acid) 
over a short gradient from 1 to 70 % B in 4 min with a 
flow rate of 20  µl/min. MassLynx 4.1 software (Waters 
Corporation) was used to collect data and deconvolute 
the protein spectra for molecular weight determination.
Alkylation of Pfs25 and amino acid analysis
Pfs25 protein derived from plant at 1  mg/ml, pH 8.0 
was reduced with 20 mM DTT at 60  °C for 30 min and 
alkylated with 40 mM iodoacetamide at 37 °C for 30 min 
in the dark; alkylation was quenched with large excess 
of β-mercaptoethanol. The extent of modified cysteines 
was analysed by amino acid analysis (AAA) at AI Bio-
Tech (Richmond, VA) with pre-column derivation using 
O-phthalaldehyde (OPA) and 9-fluorenylmethyl chloro-
formate (FMOC).
Mouse immunization and SMFA
To produce anti-Pfs25 sera in CD-1 mice for SMFA, 
10 µg of Pfs25 was formulated with ISA720 (Montanide) 
for each of the following groups: Group 1, baculovirus 
produced Pfs25; Group 2, Pichia produced Pfs25; Group 
3, positive control (plant produced Pfs25 [17]); Group 4, 
negative control (reduced alkylated plant protein Pfs25) 
and Group 5, adjuvant only control. The groups of ten 
mice were injected (intramuscularly) on day 0 and 21. 
On day 42 sera were collected and individual sera were 
tested by ELISA. In addition, sera were pooled, IgG affin-
ity purified and tested at 0.75 mg/ml as well as three-fold 
dilutions (0.250, 0.083 and 0.028 mg/ml) for SMFA activ-
ity [24]. Briefly, P. falciparum NF 54 gametocytes and 
purified IgG from mice immunized with Pfs25 were fed 
to female Anopheles stephensi mosquitoes. Mosquitoes 
were then dissected 8 days after the feeding and the num-
ber of oocysts counted to measure transmission reduc-
tion activity.
ELISA
Basic methodology of ELISA has been described by 
Miura et al. [26]. All ELISA plates were coated with plant 
produced Pfs25 [17] at 100 ng/well. Based on a standard 
curve generated with a serially diluted ELISA reference 
standard (a pool of anti-Pfs25 antisera generated against 
a plant-produced Pfs25 VLP [27]), a relative antibody 
level (i.e., ELISA units) of test sample in the same plate 
was determined.
Results and discussion
Pfs25 expressed as soluble protein in Pichia 
and baculovirus
Recombinant His-tagged Pfs25 was produced as an 
intracellular protein in E. coli, and as secreted proteins 
in Pichia and baculovirus (super Sf9) at small scale and 
purified by Ni–NTA chromatography and gel filtration 
for subsequent evaluation. In E. coli, the majority of Pfs25 
expressed was present in inclusion bodies and, therefore, 
sufficient soluble monomeric Pfs25 from E. coli lysates 
for analysis was not achievable.
It has been reported that it is possible to conduct 
refolding of Pfs25 [18] however this was not attempted 
in these studies in an effort to pursue a soluble secreted 
E. coli protein. Hereafter, Pfs25 solely from the Pichia 
and baculovirus expression systems were used for fur-
ther biochemical in vitro and functional in vivo analysis. 
A well-characterized Pfs25, derived from plant [17], was 
provided and used as a control for these newly expressed 
Pfs25 recombinant proteins.
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Characterization of purified proteins
Pfs25 purified from Pichia gave rise to a major protein 
migrating at ~20 kDa and a minor band at ~21 kDa pre-
sent at approximately 50 % of the intensity of 20 kDa band 
(Fig. 1a). The doublet corresponded to Pfs25 by western 
blotting using Pfs25 specific mAb 4B7 (Fig.  1b), which 
recognizes a β-hairpin epitope within the ILDTSNPVKT 
peptide sequence of the third EGF-like domain of native 
Pfs25 [22, 23]. Further investigation described below, 
using mass spectrometry, confirmed the doublet arose 
from protein glycosylation. For baculovirus expression, 
the purified Pfs25 protein presented as a single band of 
~20 kDa and greater than 90 % purity (Fig. 1c), with iden-
tity confirmed with the 4B7 mAb (Fig. 1d).
In addition, the proteins were evaluated utilizing SE-
HPLC to determine the aggregation state of the purified 
proteins. The Pichia and baculovirus proteins both eluted 
primarily as a monomer and contained only ~0.2  % of 
higher molecular weight species. It should be noted, the 
Pichia Pfs25 had a front shoulder (Fig. 2) that most likely 
represents a slightly larger molecular weight species or 
heterogeneity of the preparation (see intact MS analysis, 
Fig. 4a later) that is co-eluted with the monomer fraction 
(Fig. 2).
Demonstration of conformational epitopes bound by 1G2 
mAb
To further assess the conformation of the purified Pfs25 
from both expression systems the transmission-block-
ing monoclonal antibody 1G2, which can efficiently 
block the growth of parasites in mosquito vectors [28], 
was used for Western blotting analysis. A third recom-
binant Pfs25 expressed in plants [17], along with whole 
parasite lysates containing native Pfs25, were included 
for comparison with the recombinant Pfs25 (Fig. 3) pre-
pared under this study. This data indicates that the 1G2 
antibody recognized reduction sensitive, conformation 
dependent functional epitopes in both the recombinant 
and native Pfs25 derived from whole parasite lysates 
(Fig.  3). A Ponceau S control staining of the blot con-
firmed the transfer of proteins both in non-reduced and 
reduced form to the blotting membrane. The results 
provided evidence that Pfs25 produced from the Pichia 
and baculovirus contained a conformation recognized 
by this functional and conformation-dependent mono-
clonal antibody. It should be further noted, while the 
plant expressed Pfs25, contains a Glycine to Alanine 
substitution at aa131 [17, 27], there was no apparent 




























































Fig. 1 SDS‑PAGE and Western blot (4B7) of Pichia and baculovi‑
rus Pfs25. a SDS‑PAGE and b Western blot using 4B7 monoclonal 
antibody of purified Pfs25 from Pichia under reducing conditions 
(non‑reduced not show). c SDS‑PAGE and d Western blot using 4B7 
monoclonal antibody of non‑reduced and reduced purified Pfs25 
from baculovirus
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Glycosylation associated with Pichia Pfs25
Efforts to overcome post-translational modifications 
involving glycosylation have been mostly restricted to 
mutation of putative N-linked glycosylation sites [11, 
29]. In the constructs utilized here, two putative glyco-
sylation sites were mutated from N to Q (positions 112 
and 187). In light of this, SDS-PAGE revealed Pfs25 from 
Pichia presented two predominant bands (Figs. 1, 3) with 
a relative intensity of 1:2 (21 kDa:20 kDa) based on den-
sitometry. To further discern the nature of the doublets 
in Pichia-expressed Pfs25, intact mass spectrometry was 
performed to determine if the higher molecular band 
present on SDS-PAGE was indeed a result of glycosyla-
tion. The results from mass spectrometry indicated that 
Pichia Pfs25 contained added sugar adducts, as evi-
denced by the mass difference of 162 and 324 Daltons 
(Fig.  4a), the expected mass difference due to the pres-
ence of sugar moieties. Pfs25 produced in Pichia has been 
previously reported with O-glycosylation [11], where 
mannose residues, typical of P. pastoris [30, 31], were 
identified. It should be noted that while previously three 
possible N-linked glycosylation sites were mutated [11], 
in the studies reported here, only two such sites were 
mutated. The decision to mutate only two sites was based 
on historical literature [17] as well as a predictive analy-
sis using NetNGlyc 1.0 Server [32] and GlycoEP [33]; as 
the asparagine at position 165 had a consistent low prob-
ability (<50 %) of potential glycosylation. In comparison, 
the baculovirus expressed Pfs25 presented as a single 
predominant band and >90 % pure based on SDS-PAGE 
densitometry indicating absence of glycosylation.
As shown in the same intact mass analysis (Fig.  4a; 
Table  1) the Pichia Pfs25 mass matched the oxidized 
form of Pfs25 (19,592.5 Da), which implicated the pres-
ence of 11 pairs of disulfides [14]. The intact mass anal-
ysis of baculovirus Pfs25 (Fig.  4b; Table  1) matched the 
predicted molecular mass of Pfs25, consistent with the 
absence of glycosylation with all cysteines in the oxidized 
form. A minor species 186 Da lower than the main spe-
cies (Fig.  4b) was however present in this baculovirus 
preparation, and N-terminal sequencing showed that this 
minor species was a N-terminal truncate of the first two 
amino acids (D-A). Such truncation is consistent with 
the probability of signal peptide cleavage sites as pre-
dicted by SignalP [34]. This truncated form was present 
at approximately 24 % the full-length protein based on a 
semi-quantitative estimate from N-terminal sequencing 
data by Edman degradation [35].
Cysteine oxidization and analysis of homogeneity
To confirm that recombinant Pfs25 proteins were indeed 
in the oxidized form, the number of thiol groups exposed 
on the protein surface with and without 2 M guanidine 
HCl was measured. Both proteins (Pichia and baculo-
virus) contained <0.1  % free thiol, as no fluorescence 
signal was detected above the buffer control, support-
ing the observations that all 22 cysteines were oxidized 
and disulfide paired as suggested by the intact mass 































Retenon Time (min) 
a b
Fig. 2 SE‑HPLC of Pichia and baculovirus Pfs25. a Pfs25 from Pichia (black line) and baculovirus (dashed red line) eluted predominantly as a 
monomer. Arrows indicate shoulder observed for Pichia Pfs25 that most likely represents a higher molecular weight component co‑eluting with 
monomer. The shoulder present for Pichia Pfs25 could not be fully resolved and integrated. Molecular weight gel filtration standards (Bio‑Rad, Her‑
cules, CA) indicated a monomer, with Pfs25 eluting at its expected molecular weight (between 44 and 17 kDa). b Normalized absorbance for eluted 
monomer peaks
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observations described above (Fig. 4). Further, the Plant 
Pfs25 protein used as a control and comparator through-
out these studies, was also tested and confirmed to con-
tain <0.1 % free thiol.
A reverse phase HPLC (RP-HPLC) assay was utilized to 
further quantify the inhomogeneity (Fig. 5) of the Pichia 
produced Pfs25 in comparison to the baculovirus prod-
uct. The analysis utilizing this RP-HPLC method showed 
that the Pichia produced Pfs25 was approximately 66 % 
pure (Fig.  5a), whereas in contrast the baculovirus pro-
duced Pfs25 appeared to be of 89 % purity (Fig. 5b).
Elicitation of functional antibodies
After observing glycosylation in Pichia-expressed Pfs25, 
whether this modification would affect the biologi-
cal activity of Pfs25, was investigated. While a previous 
study utilizing DNA vaccination showed limited detri-





























Fig. 3 SDS‑PAGE and Western blot using a conformational antibody 
of various Pfs25 proteins and native parasite extract. a SDS‑PAGE, b 






















Fig. 4 Intact mass spectrometry analysis of recombinant Pfs25 
proteins. Intact mass spectrometry analysis of a Pfs25 derived from 
Pichia and b Pfs25 expressed from baculovirus. Mass determinations 
are indicated in arrow boxes, with the addition of mass adduct noted 
from the parent, predominant mass
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activity [29], data on the administration of glycosylated 
recombinant antigens was limited. It is reasoned that 
glycosylation could change the overall protein conforma-
tion or occlude sites that may elicit functional antibody 
responses. To answer this, polyclonal antibodies were 
raised in mice to the various recombinant Pfs25 and the 
transmission reducing activity of the antisera measured 
by the reduction of oocysts in mosquito midguts using 
a standard membrane feeding assay [24]. Before immu-
nization, it was confirmed that all purified proteins con-
tained <2 EU/mg of endotoxin.
For the immunizations, the plant protein was used as 
a positive control and a reduced alkylated form of the 
plant protein was used as a negative control to confirm 
the importance of disulfide bond formation of Pfs25. Fur-
ther analysis of the reduced alkylated Pfs25 preparation 
via amino acid composition analysis recovered 13 car-
boxymethylated cysteine, indicating at least 13 out of 22 
cysteines were modified by alkylation.
The antisera raised in mice were evaluated by ELISA 
for antibody titers and their functional activities were 
evaluated by SMFA. The ELISA titers of mouse sera 
Table 1 Physical properties of recombinant Pfs25










Pichia 19,614.5 19,592.5 19,592.8 ± 0.5 0.3 AKVTV








































Main peak: 66 ± 2 % (Total peak area)












Main peak: 89 ± 1 % (Total peak area)
Fig. 5 Reverse phase HPLC analysis of recombinant Pfs25 proteins. Reverse phase HPLC of a Pichia derived Pfs25 and b Baculovirus derived Pfs25
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raised by Pfs25 proteins of different expression systems 
(Groups 1–3) were not statistically different between the 
Pfs25 groups as determined through a non-parametric 
Kruskal–Wallis test and Dunn’s multiple comparisons 
test (Fig.  6). Statistical significance was determined, 
however, between each of the Pfs25 non-reduced groups 
(Groups 1, 2 or 3) and the control (Group 5) with p values 
<0.01 (Fig.  6). To probe for the elicitation of functional 
antibodies, the reduction of oocyst density was measured 
in an SMFA (Table  2). The results were consistent with 
previous observations of the Pfs25 immunogenicity [17] 
with each protein preparation demonstrating the ability 
to elicit transmission reducing activity >99 % at high con-
centrations of antibody. Purified IgG at a concentration 
of 750  μg/ml (Experiment 1, Table  2), elicited by non-
reduced Pfs25 proteins did not reveal differences between 
different methods of preparation, and thus was further 
tested at threefold dilutions (Experiment 2, Table 2). Even 
at the lowest concentration tested (28 μg/ml), no statis-
tically significant difference was observed among non-
reduced Pfs25 groups (Groups 1–3) with all transmission 
reducing activity ≥98  %. Therefore, in Pichia expressed 
Pfs25 (Group 2), glycosylation did not apparently affect 
the transmission reducing activity as detected here, with 
results comparable to Pfs25 produced from baculovirus 
(Group 1) or plant (Group 3) that each exhibited little or 
no glycosylation (Table  2). In Group 4, where disulfides 
were disrupted, the sample produced lower antibody 
titers (Fig. 6) and yielded negligible transmission reduc-
ing activity (Table 2). This experiment confirmed that the 
conformation of Pfs25 held by disulfide bonds was essen-
tial to generate transmission reducing antibodies in mice, 
whereas glycosylation may not be as much of a concern 
for functional activity as previously thought. Moreover, 
Pfs25 produced from Pichia and baculovirus are active 
in raising functional antibodies that convey transmission 
reducing activity.
Conclusions
In the search for a transmission blocking vaccine based on 
Pfs25, the malaria community has been guided by the con-
cept that an immunogen should mimic as much as possi-
ble the Pfs25 found on the surface of the parasite. In the 
current studies, Pfs25 was expressed, purified, and char-
acterized in the Pichia and baculovirus systems. In the E. 
coli system, in spite of numerous attempts, soluble, mono-
meric Pfs25 was not achieved. While it may be possible to 
generate native configuration Pfs25 using refolding meth-
ods from the generated inclusion bodies [18], this was not 
pursued given the promising nature of results from the 
other expression systems. In contrast, both Pichia and 
Fig. 6 ELISA titer of individual CD‑1 mice immunized with Pfs25. Box 
whisker plot of ELISA titer of CD‑1 mice immunized with Pfs25 and 
controls presented in log scale of ELISA Units (EU). All serum samples 
were tested against plant Pfs25, not against immunogens. Line 
denotes median value for group, box shows 25–75 % interval and 
whiskers show min and maximum values (****p value <0.0001, **p 
value <0.01)
Table 2 Functional evaluation of antibodies against Bacu-
lovirus, Pichia and plant Pfs25 proteins
Groups of ten mice were injected with 10 µg of Pfs25 adjuvanted with 
montanide on days 0 and 21. On day 42 sera were pooled, and the purified IgGs 
were tested at the indicated concentrations by SMFA
a IgG concentration (μg/ml) in a feeder
b Arithmetic mean (range) of oocysts intensity from 20 mosquitoes
c Percent inhibition of mean oocyst intensity and the 95 % confidence interval 
(95 % CI)
d Two-sided p values for testing whether % inhibition is significantly different 
from 0
Sample Conca Mean Oocb % inhibitionc p valued
Experiment 1
 Baculovirus 750 0.1 (0, 1) 100 (99, 100) <0.001
 Pichia 750 0 (0, 0) 100 (100, 100) <0.001
 Plant 750 0 (0, 0) 100 (100, 100) <0.001
 Plant (reduced) 750 25.1 (3, 45) 3 (−176, 67) 0.945
 Control 750 25.8 (0, 58) N/A N/A
Experiment 2
 Baculovirus 250 0 (0, 0) 100 (100, 100) <0.001
83 0 (0, 0) 100 (100, 100) <0.001
28 0.4 (0, 2) 98 (94, 100) <0.001
 Pichia 250 0 (0, 0) 100 (100, 100) <0.001
83 0 (0, 0) 100 (100, 100) <0.001
28 0.3 (0, 2) 99 (95, 100) <0.001
 Plant 250 0 (0, 0) 100 (100, 100) <0.001
83 0 (0, 0) 100 (100, 100) <0.001
28 0.1 (0, 2) 100 (99, 100) <0.001
 Control 750 17.1 (0, 62) N/A N/A
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baculovirus expression resulted in proteins with many 
characteristics consistent with the expected structure of 
the native Pfs25. In Pichia, the expressed Pfs25 was likely 
glycosylated, despite mutations of probable N-linked sites, 
and consequently resulted in multiple molecular weight 
forms. The baculovirus expressed Pfs25 presented a non-
glycosylated and homogeneous recombinant protein. 
Through multiple methods, including the free thiol assay 
and intact mass analysis, both Pichia and baculovirus pro-
duced Pfs25 proteins contained 11 pairs of disulfides as 
expected. Two transmission blocking monoclonal anti-
bodies 4B7 [22, 23] and 1G2 [28], also bind well to both 
Baculovirus and Pichia produced Pfs25 protein suggesting 
proper folding of the purified proteins.
The ability to elicit functional transmission blocking 
antibodies is the most important characteristic of any 
protein preparation to be considered for the generation 
of a vaccine. Given that P. falciparum apparently lacks 
such modifications, glycosylation has been a concern in 
the development of recombinant antigens for use as TBV 
and other malaria vaccine candidates. In this study, the 
evidence of limited glycosylation present in Pichia pro-
duced Pfs25 did not appear to diminish the ability to elicit 
transmission blocking antibodies and was consistent with 
findings carried out with Pfs25 DNA vaccines evaluating 
glycosylation of Pfs25 [29]. It is important, however, to 
recognize the limitations of SMFA testing, as it may not 
detect subtle differences in potency. It may also be possi-
ble to separate the various forms of Pfs25 (glycosylated and 
non-glycosylated) and in conjunction with a dose ranging 
study (versus a single 10 µg) to better determine the effi-
cacy of a glycosylated Pfs25 as compared to non-glyco-
sylated forms. As potent transmission blocking antibodies 
were elicited by the aglycosylated, homogeneous and sta-
ble Pfs25 produced from the baculovirus, this production 
system may be attractive for further vaccine development.
Lastly, the status of the disulfide bonds formed in the 
recombinant proteins was investigated. Proteins pro-
duced in Pichia, baculorvirus as well as the control plant 
produced protein showed evidence of no free cysteines 
by two methods, free thiol and mass spectrometric analy-
sis. When these disulfide bonds are disrupted by reduc-
tion and alkylation the elicitation of functional antibodies 
(as measured by SMFA) was diminished, demonstrat-
ing that at least some of the disulfide bonds are essential 
for the function of the Pfs25 protein as an immunogen. 
Taken together, these results indicate that both Pichia 
pastoris and baculovirus expression systems have poten-
tial for the production of Pfs25 based transmission-
blocking vaccines.
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